ArticleCancer medicine2023
Changes in the disease burden of breast cancer along with attributable risk factors in China from 1990 to 2019 and its projections: An analysis of the global burden of disease study 2019.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic value of circulating miR-155 for breast cancer: a meta-analysis.Frontiers in oncology · 2024Pooled it
- Recent Advances (2020-2025) in Estrogen and ER-Positive Breast Cancer: Receptor Signaling, Tumor Microenvironment, Endocrine Therapy Resistance and Innovative Treatment Strategies-A Comprehensive Review.Cancer management and research · 2026Review
- Temporal Trends in Mortality of Female Cancers Among Women and the Impact of COVID-19 in Low- and Middle-Income Countries, 1990-2023: An Age-Period-Cohort Analysis from the Global Burden of Disease Study 2023.International journal of women's health · 2026Article
- A Competency-Based Evaluation Index System for Recertification of Breast Specialist Nurses: A Delphi Study in China.Journal of multidisciplinary healthcare · 2026Article
- Impact of COVID-19 care reorganization on the prognosis of patients with bladder urothelial carcinoma: a multicentric retrospective study.The Canadian journal of urology · 2025Article
- Article
- Chitosan-Based Nanoparticles for Twist1 Knockdown in 4T1 Cells.Macromolecular bioscience · 2025Article
- A cross-sectional study of serum lipids, body mass index and age relationships with breast cancer risk.World journal of surgical oncology · 2025Article
- Epidemiology of breast cancer in Chinese women from 1990 to 2021: a systematic analysis and comparison with the global burden.BMC cancer · 2025Article
- Performance of low- and high-temporal-resolution DCE-MRI texture analysis in distinguishing breast lesions from background enhancement.American journal of translational research · 2025Article
- Value of altered methylation patterns of genes RANBP3, LCP2 and GRAP2 in cfDNA in breast cancer diagnosis.Journal of medical biochemistry · 2024Article
- Article
- Prediction of ADMET Properties of Anti-Breast Cancer Compounds Using Three Machine Learning Algorithms.Molecules (Basel, Switzerland) · 2023Article
- Changes in the disease burden of breast cancer along with attributable risk factors in China from 1990 to 2019 and its projections: An analysis of the global burden of disease study 2019.Cancer medicine · 2023Article
- Global estimates of rehabilitation needs and disease burden in tracheal, bronchus, and lung cancer from 1990 to 2019 and projections to 2045 based on the global burden of disease study 2019.Frontiers in oncology · 2023Article
- Diagnostic value of mammography density of breast masses by using deep learning.Frontiers in oncology · 2023Article
- Research Progress on Dual-Modal Fluorescence-MRI Molecular Imaging of Molecular Probes in Breast Cancer.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the secular trends in breast cancer burden with attributable risk factors, and make projections over time, which would contribute to the control and prevention of breast cancer.
methodsWe extracted detailed data on breast cancer incident cases and age-standardized incidence rate (ASIR), deaths and age-standardized mortality rate (ASMR), disability-adjusted life-years (DALYs), and age-standardized DALYs rate (ASDR), as well as the attributable risk factors in China from the Global Burden of Diseases Study 2019. The estimated annual percentage change (EAPC) was calculated to quantify the changing trends. The national DALYs attributable to Socio-demographic Index (SDI) values were also presented. Projections to 2030 were estimated using the Bayesian age-period-cohort model.
resultsFrom 1990 to 2019, the number of breast cancer incident cases increased fourfold to 375,484, with deaths and DALYs over doubling to 96.306 and 2,957,454, respectively. The ASIR (EAPC = 2.84; 95% CI, 2.74-2.95) and ASMR (EAPC = 0.06; 95% CI, 0.00-0.12) increased, while the ASDR decreased with the EAPC of -0.13 (95% CI, -0.19 to -0.06) at the same period. The ASDR varied across provincial regions, which appeared to be in a wave-like upcurve with SDI values increasing. High body mass index became the first contribution to breast cancer DALYs for females in 2019, and alcohol use for males. Breast Cancer incident cases and deaths would increase to 587.7 and 125.6 thousand in 2030, of which there will be 577.1 and 122.7 thousand for females, and 10.6 and 2.9 thousand for males, respectively.
conclusionBreast cancer remains a major public health problem in China. The absolute burden has been increasing over time, and varied across sex and regions. To control the potential risk factors and develop specific strategies will help to reduce the disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.